A Double-Blind Placebo-Controlled Preliminary Study of the Efficacy, Safety and Tolerability of ST101 Tablets in the Treatment of Alzheimer's Disease.
Latest Information Update: 09 Nov 2021
At a glance
- Drugs ST 101 (Primary)
- Indications Alzheimer's disease
- Focus Therapeutic Use
- Sponsors Sonexa Therapeutics
- 27 Dec 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 24 Aug 2010 Planned end date changed from 1 Aug 2010 to 1 Sep 2010 as reported by ClinicalTrials.gov.
- 26 May 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.